Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Janet A Dunn

Showing results (31-40 of 59) with videos related to

Pageof 6
Sort By:
Plos One|July 9, 2016
The Relationship between Common Genetic Markers of Breast Cancer Risk and Chemotherapy-Induced Toxicity: A Case-Control StudyLeila Dorling, Siddhartha Kar, Kyriaki Michailidou, et al.
The New England Journal of Medicine|March 19, 2004
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancerJohn P Neoptolemos, Deborah D Stocken, Helmut Friess, et al.
Health Technology Assessment (Winchester, England)|April 15, 2017
PET-NECK: a multicentre randomised Phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancerHisham Mehanna, Chris C McConkey, Joy K Rahman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 7, 2014
Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with PaclitaxelJean E Abraham, Qi Guo, Leila Dorling, et al.
The Lancet. Oncology|January 19, 2010
Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601)John M S Bartlett, Alison F Munro, Janet A Dunn, et al.
Health Technology Assessment (Winchester, England)|February 12, 2016
OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancerRobert C Stein, Janet A Dunn, John M S Bartlett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2018
Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)Annie M Young, Andrea Marshall, Jenny Thirlwall, et al.
The Lancet. Oncology|December 17, 2013
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trialHugo E R Ford, Andrea Marshall, John A Bridgewater, et al.
BJU International|March 5, 2013
A comparison of patient and tumour characteristics in two UK bladder cancer cohorts separated by 20 yearsRichard T Bryan, Maurice P Zeegers, Eline H van Roekel, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 16, 2017
Value of Information Analysis of Multiparameter Tests for Chemotherapy in Early Breast Cancer: The OPTIMA Prelim TrialPeter S Hall, Alison Smith, Claire Hulme, et al.
Pageof 6

Showing results (31-40 of 59) with videos related to

Sort By:
Pageof 6
Plos One|July 9, 2016
The Relationship between Common Genetic Markers of Breast Cancer Risk and Chemotherapy-Induced Toxicity: A Case-Control StudyLeila Dorling, Siddhartha Kar, Kyriaki Michailidou, et al.
The New England Journal of Medicine|March 19, 2004
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancerJohn P Neoptolemos, Deborah D Stocken, Helmut Friess, et al.
Health Technology Assessment (Winchester, England)|April 15, 2017
PET-NECK: a multicentre randomised Phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancerHisham Mehanna, Chris C McConkey, Joy K Rahman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 7, 2014
Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with PaclitaxelJean E Abraham, Qi Guo, Leila Dorling, et al.
The Lancet. Oncology|January 19, 2010
Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601)John M S Bartlett, Alison F Munro, Janet A Dunn, et al.
Health Technology Assessment (Winchester, England)|February 12, 2016
OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancerRobert C Stein, Janet A Dunn, John M S Bartlett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2018
Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)Annie M Young, Andrea Marshall, Jenny Thirlwall, et al.
The Lancet. Oncology|December 17, 2013
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trialHugo E R Ford, Andrea Marshall, John A Bridgewater, et al.
BJU International|March 5, 2013
A comparison of patient and tumour characteristics in two UK bladder cancer cohorts separated by 20 yearsRichard T Bryan, Maurice P Zeegers, Eline H van Roekel, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 16, 2017
Value of Information Analysis of Multiparameter Tests for Chemotherapy in Early Breast Cancer: The OPTIMA Prelim TrialPeter S Hall, Alison Smith, Claire Hulme, et al.
Pageof 6